Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

16 Sept 2019

Abstract excerpt

BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31537406
DOI: 10.1016/j.eururo.2019.08.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation CarriersPMID 31537406Read ↗

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.Semantic proximity Read ↗

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.Semantic proximity Read ↗

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.Semantic proximity Read ↗

Prostate Cancer Screening in a New Era of Genetics.Semantic proximity Read ↗

Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.Semantic proximity Read ↗

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.Semantic proximity Read ↗

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Semantic proximity Read ↗

High-Grade Prostate Adenocarcinoma in a BRCA2 Germline Mutation Carrier: Precision Oncology and Familial Cascade Testing: a case reportSemantic proximity Read ↗

Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation?Semantic proximity Read ↗

Prostate cancer risk-stratification using proteomic estimation of KLK3 improves accuracy in screening applications: a population-based cohort study in the UK BiobankSemantic proximity Read ↗

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.Semantic proximity Read ↗

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.